Daily ReportOct 22, 2026
Sepsis, October 22 edition
We read 23 papers and selected 3.
Summary
The most impactful studies combined translational antibiotic discovery with clinically actionable evidence on antifungal timing and phenotype-guided empiric therapy. A new abaucin derivative showed potent activity against carbapenem-resistant Acinetobacter baumannii and protected mice from sepsis, while multicenter clinical data demonstrated a steep survival penalty for delayed pathogen-appropriate antifungal therapy in Candida septic shock. A dual-cohort analysis further suggested that empiric carbapenem therapy may benefit a specific SENECA phenotype but offers no overall mortality advantage.
Research Themes
- Novel antibiotics for multidrug-resistant sepsis pathogens
- Time-critical pathogen-directed therapy in septic shock
- Precision empiric antimicrobial therapy using sepsis phenotypes
Selected Articles
1. Structure-activity relationship (SAR) studies of abaucin derivatives targeting the lipoprotein transport system in Acinetobacter baumannii.
This medicinal chemistry study synthesized 30 abaucin derivatives and identified compound 28 as a lead against A. baumannii. Compound 28 inhibited the LolF/D complex, had a minimum inhibitory concentration of 0.5 μg/mL, showed rapid bactericidal activity and low spontaneous resistance, and achieved 100% protection when combined with polymyxin B in a mouse sepsis model.
Impact: The study advances a mechanistically distinct antibiotic program against a critical-priority pathogen and links medicinal chemistry optimization to in vivo sepsis protection. It provides a concrete lead for further pharmacology, toxicology, and therapeutic development.
Clinical Implications: Compound 28 is not yet a clinical treatment, but it could support development of a pathogen-selective therapy for carbapenem-resistant A. baumannii sepsis. Clinical translation will require confirmation of human pharmacokinetics, tissue penetration, toxicity, resistance selection, and efficacy in infection models that more closely reproduce human disease.
Key Findings
- Thirty abaucin derivatives were designed and synthesized to define structure-activity relationships.
- Compound 28 inhibited the LolF/D lipoprotein transport complex and showed a minimum inhibitory concentration of 0.5 μg/mL against A. baumannii.
- Compound 28 displayed rapid and complete bactericidal activity, low spontaneous resistance, and 100% protection when combined with polymyxin B in a mouse sepsis model.
Methodological Strengths
- Systematic medicinal chemistry optimization linked scaffold features to antibacterial activity.
- The lead compound was evaluated with biochemical, microbiological, kinetic, resistance, safety, and mouse sepsis assays.
Limitations
- The efficacy evidence is preclinical and was generated in a mouse model rather than in humans.
- The abstract does not provide detailed pharmacokinetic, dose-exposure, or comparative efficacy data against current standard therapies.
Future Directions: Future studies should define pharmacokinetic-pharmacodynamic targets, optimize dosing and formulation, test monotherapy and combination regimens in multiple infection models, evaluate resistance mechanisms, and conduct formal toxicology before first-in-human studies.
Carbapenem-resistant A. baumannii (CRAB) has been classified by the World Health Organization (WHO) as a critical priority antibiotic-resistant pathogen, making it one of the highest priorities for global antibiotic development. In 2023, abaucin, a narrow-spectrum antibiotic selectively targeting the lipoprotein transport system in Acinetobacter baumannii, was identified through deep learning-based screening. In this study, we designed and synthesized 30 abaucin derivatives to further explore the structure-activity relationship (SAR). SAR analysis revealed that the spirocyclic scaffold, linker length and aromatic substituents played critical roles.
2. Delay From Hypotension Onset to Appropriate Antifungal Therapy Initiation Is the Critical Determinant of Outcome in Candida Septic Shock.
In 850 adults with culture-positive Candida septic shock from 32 hospitals, each hour of delay in pathogen-appropriate antifungal therapy after persistent hypotension was associated with higher odds of death. Survival was 86% when treatment began within 2 hours, but declined by approximately 5% per hour thereafter; the median time to appropriate therapy was 32.3 hours.
Impact: This large multicenter cohort quantifies an exceptionally steep time-to-treatment relationship in Candida septic shock. The findings support rapid diagnostic and therapeutic pathways for invasive candidiasis, while also exposing a major systems-level gap because fewer than one in five patients received appropriate therapy within 6 hours.
Clinical Implications: When Candida septic shock is suspected or documented, clinicians should prioritize immediate pathogen-appropriate antifungal therapy after persistent hypotension, alongside source control and hemodynamic resuscitation. Hospitals should develop rapid fungal diagnostics, empiric-treatment protocols for high-risk patients, and antimicrobial stewardship pathways that allow prompt de-escalation when Candida is not confirmed.
Key Findings
- Among 850 adults with Candida septic shock, only 16.9% received appropriate antifungal therapy within 6 hours of hypotension onset.
- The adjusted odds of death increased by 1.045 for each hour of delay in appropriate antifungal therapy.
- Hospital survival was 86% with treatment within 2 hours and decreased by approximately 5% per hour with subsequent delay.
Methodological Strengths
- The cohort included 850 patients across 32 academic and community hospitals in three countries.
- Multivariable and sensitivity analyses evaluated the association across infection types, pathogens, and antifungal drug classes.
Limitations
- The retrospective design cannot establish that treatment delay caused mortality and is vulnerable to confounding by illness severity and recognition bias.
- The study period extended from 1989 to 2018, so diagnostic practices, antifungal agents, and contemporary sepsis care may differ from current practice.
Future Directions: Prospective studies should test rapid blood-culture identification, fungal biomarkers, risk-based empiric antifungal pathways, and sepsis-team response systems designed to initiate appropriate therapy within the first hours of persistent hypotension.
OBJECTIVES: To determine the effect of delays in initiation of appropriate antifungal therapy from the initial onset of persistent hypotension to the outcome of Candida septic shock. DESIGN: Retrospective cohort study. SETTING: A total of 32 academic and community hospitals in Canada, the United States, and Saudi Arabia (July 1989 to June 2018). PATIENTS: A total of 850 adult patients with culture-positive Candida septic shock. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Out of 850 patients with Candida septic shock, 69.2% patients (589) received appropriate antifungal therapy after the onset of persistent hypotension. A strong relationship was observed between the delay in initiation of pathogen-appropriate antifungal (PAA) therapy and hospital survival.
3. Initial empiric carbapenem versus non-carbapenem β-lactam/β-lactamase inhibitor therapy in sepsis across simplified SENECA phenotypes: a retrospective study of two independent cohorts.
Across MIMIC-IV and an independent hospital cohort, initial empiric carbapenem therapy was not associated with lower 28-day mortality overall. However, a consistent treatment-by-phenotype interaction suggested lower mortality in the SENECA γ phenotype, while carbapenem exposure in MIMIC-IV was associated with longer hospitalization and more frequent detection of fungal organisms and Clostridioides difficile.
Impact: The study challenges routine escalation to carbapenems by showing no overall mortality benefit and possible microbiological trade-offs. Replication of a phenotype-specific signal in two independent cohorts supports precision antimicrobial trials rather than one-size-fits-all empiric therapy.
Clinical Implications: Empiric carbapenem use should not be assumed to improve outcomes for all patients with sepsis. Clinicians should integrate local resistance patterns, infection source, prior antimicrobial exposure, patient severity, and potentially validated sepsis phenotypes, while balancing coverage against risks of ecological harm and Clostridioides difficile infection.
Key Findings
- In MIMIC-IV and the independent hospital cohort, empiric carbapenem therapy was not associated with lower 28-day mortality overall.
- A treatment-by-phenotype interaction was observed in both cohorts, with lower mortality associated with carbapenems in the SENECA γ phenotype.
- In MIMIC-IV, carbapenem therapy was associated with longer hospitalization and more frequent detection of fungal organisms and Clostridioides difficile.
Methodological Strengths
- The analysis used two independent cohorts comprising 4,091 MIMIC-IV patients and 405 patients from a separate hospital cohort.
- Inverse probability of treatment weighting and weighted regression addressed measured treatment-selection differences, and phenotype interactions were prespecified for evaluation.
Limitations
- The retrospective design leaves the possibility of residual confounding, indication bias, and misclassification of the initial empiric regimen or SENECA phenotype.
- The phenotype-specific mortality findings are associative and require prospective validation before guiding individual antibiotic selection.
Future Directions: Prospective phenotype-stratified trials should test whether SENECA-guided antibiotic selection improves survival while reducing unnecessary carbapenem exposure, fungal overgrowth, Clostridioides difficile infection, and other ecological harms.
PURPOSE: Whether initial empiric carbapenem therapy is associated with better outcomes than non-carbapenem β-lactam/β-lactamase inhibitor (BL/BLI) therapy in sepsis remains uncertain. We examined this association overall and across simplified Sepsis Endotyping in Emergency Care (SENECA) phenotypes. METHODS: This retrospective study included 4,091 patients from MIMIC-IV and 405 patients from a single-center hospital cohort. Initial therapy was defined by the first eligible carbapenem or BL/BLI regimen initiated within 24 h of admission. The primary outcome was 28-day mortality.